Graphical timeline: Gram-negative spectrum antimicrobials used as empirical treatment.

https://doi.org/10.1371/journal.pone.0297161.g001
Open external identifier URL

figure

posted on 2024-01-26, 18:31 authored by Ingvar Ludwig Augusto de Souza, Paola Cappellano, Diogo Boldim Ferreira, Maria Daniela Bergamasco, Thomas Cardoso das Chagas Neto, Fabio Rodrigues Kerbauy, Otavio Carvalho Guimarães Baiocchi, Antonio Carlos Campos Pignatari

<p>The figure illustrates the empirical treatment choices made in the 65 episodes of CRKp-BSI over the 10-year study period, highlighting the dynamic and diverse nature of therapeutic decisions. Each row represents an antimicrobial used as empirical treatment given the episode’s number, yearly stratified (columns). *episode #10 did not received empirical treatment since it was non-neutropenic or had any signs of organ disfunction; antimicrobial therapy was started right after the outcome of initial microbiological tests.</p>

History

Related Materials

1.
DOI - Is supplement to Carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infections in haematological malignances and hematopoietic stem cell transplantation: Clinical impact of combination therapy in a 10-year Brazilian cohort

Usage metrics

PLOS ONE

Categories

Keywords

polymyxin b co mucosal barrier injury klebsiella pneumoniae </invasive fungal disease adjusted hazard ratio 9 %, respectively 06 – 0 microbiological data revealed 20 – 7 year brazilian cohort polymyxin b resistant div >< p bsi episodes occurring bacterial bloodstream infections 40 – 10 ci ]: 0 ahr ]: 0 14 – 0 day mortality crkp year cohort bloodstream infections day mortality microbiological aspects mortality rates 7 %).7 %)retrospectively studied resistance phenotype regarding treatment primary cause overall survival less common january 2010 hsct recipients hsct ).haematological patients haematological malignancies haematological malignances gastrointestinal tract favorable correlation describe clinical deemed appropriate december 2019 confidence interval combination therapy clinical impact bsi caused better outcome amikacin resistance acute leukemias 65 crkp 6 %)31 patients 16 samples 14 individuals 002 ).

Licence

Exports